专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005021710A3 CHIMERIC MOLECULES AND METHODS OF USE 审中-公开
标题翻译： CHIMERIC分子和使用方法
公开(公告)号：WO2005021710A3
公开(公告)日：2008-01-17
申请号：PCT/US2004017119
申请日：2004-06-02
申请人： UNIV MIAMI
发明人： SHIN SEUNG-UON , MORRISON SHERIE L , ROSENBLATT JOSEPH D
IPC分类号： C12P21/08 , A61K39/00 , C07H21/04 , C07K14/78 , C07K16/28 , C07K16/32 , C07K16/46
CPC分类号： C07K16/32 , A61K2039/505 , C07K14/78 , C07K2317/622 , C07K2319/00
摘要： Chimeric molecules comprising endostatin and all or a portion of an Ig (Ig) molecule are used to treat tumors. A chimeric molecule, including endostatin fused to an Ig domain of an anti-HER2/neu antibody exhibited longer serum half-life and stability than native endostatin. 125 I-labeled anti HER2/neu IgG3-endostatin chimeric molecule and anti-HER2/neu IgG3-endostatin was 6 fold faster than that of anti-HER2/neu IgG3 (CLss=0.374 and 0.062ml/min/kg, respectively), however, the specific tumor radiolocalization indices of anti-HER2/neu IgG3-endostatin were greater than those of anti-HER2/neu IgG3. Anti-HER2/neu IgG3-endostatin inhibited tumor growth more effectively than endostatin alone, anti-HER2/neu IgG3 antibody, or the combination of antibody and endostatin.
摘要翻译：包含内皮抑素和Ig（Ig）分子全部或部分的嵌合分子用于治疗肿瘤。融合到抗HER2 / neu抗体的Ig结构域的内含抑制素的嵌合分子比天然内皮抑素表现出更长的血清半衰期和稳定性。 125I标记的抗HER2 / neu IgG3-内皮抑制素嵌合分子和抗HER2 / neu IgG3-内皮抑制素比抗HER2 / neu IgG3快6倍（CLss = 0.374和0.062ml / min / kg），然而，抗HER2 / neu IgG3-内皮抑制素的特异性肿瘤放射性定位指数大于抗HER2 / neu IgG3的特异性肿瘤放射性定位指数。抗HER2 / neu IgG3-内皮抑制素比单独内皮抑制素，抗HER2 / neu IgG3抗体或抗体和内皮抑制素的组合更有效地抑制肿瘤生长。

IPRDB

热门服务

关于我们

友情链接

联系方式